Sun Yanhong, Tan Huixin, Wang Fenghe, Hu Jiahuan, Duan Xiaoyan, Bai Wanting, Wu Jinjin, Bai Jie, Hu Jinping
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study, Beijing Key Laboratory of Active Substances Discovery and Drug Ability Evaluation, Department of Drug Metabolism, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Chem Res Toxicol. 2025 Feb 17;38(2):281-295. doi: 10.1021/acs.chemrestox.4c00418. Epub 2025 Feb 3.
Alkaloids, a class of low-molecular-weight nitrogenous compounds, attract a great deal of interest because of their biological activities and therapeutic potential. Yet, surprisingly little is known about their interactions with drug transporters, especially Organic Anion Transporting Polypeptide 1B1 (OATP1B1), a liver-specific uptake transporter, which is closely associated with drug-induced liver injury (DILI). This study aims to investigate the inhibitory effects of 160 alkaloids on OATP1B1, assess the hepatoprotective effects against bosentan-induced liver injury, and elucidate the structure-activity relationships of alkaloids with OATP1B1. Four alkaloids, including dihydroberberine, deacetyltaxol, dihydrocapsaicin, and tetrahydropalmatine, significantly inhibited OATP1B1 transport activity in OATP1B1-HEK293 cells (>50%), which reduced the OATP1B1-mediated uptake of methotrexate and microcystin-LR, and consequently decreased their cell toxicity. In bosentan-induced liver injury models, 4 alkaloids reduced serum total bile acid (TBA) levels and liver concentration of bosentan to different degrees, especially deacetyltaxol, which exhibited the most potent hepatoprotective effect against bosentan. The pharmacophore model suggested that the critical pharmacophores of alkaloid inhibitors are hydrogen bond acceptors and hydrophobic groups. Our findings pave the way for predicting the potential risks of alkaloids-containing food/herb-drug interactions in humans and optimizing the alkaloid structure for alleviating OATP1B1-related DILI.
生物碱是一类低分子量含氮化合物,因其生物活性和治疗潜力而备受关注。然而,令人惊讶的是,人们对它们与药物转运体的相互作用知之甚少,尤其是有机阴离子转运多肽1B1(OATP1B1),一种肝脏特异性摄取转运体,它与药物性肝损伤(DILI)密切相关。本研究旨在研究160种生物碱对OATP1B1的抑制作用,评估其对波生坦诱导的肝损伤的肝保护作用,并阐明生物碱与OATP1B1的构效关系。四种生物碱,包括二氢小檗碱、去乙酰紫杉醇、二氢辣椒素和延胡索乙素,显著抑制了OATP1B1-HEK293细胞中OATP1B1的转运活性(>50%),这降低了OATP1B1介导的甲氨蝶呤和微囊藻毒素-LR的摄取,从而降低了它们的细胞毒性。在波生坦诱导的肝损伤模型中,4种生物碱不同程度地降低了血清总胆汁酸(TBA)水平和波生坦的肝脏浓度,尤其是去乙酰紫杉醇,它对波生坦表现出最有效的肝保护作用。药效团模型表明,生物碱抑制剂的关键药效团是氢键受体和疏水基团。我们的研究结果为预测含生物碱的食物/草药-药物相互作用在人体内的潜在风险以及优化生物碱结构以减轻与OATP1B1相关的DILI铺平了道路。